Salience Clinical Introduces S2G Framework Pairing AI Screening with Physician-Executive GestaltSubmissions

New methodology provides biopharma and medtech sponsors an auditable path from multimodal clinical data entropy to regulatory-ready narratives.

PRINCETON, N.J., United States, 15th Sep 2026 –  Salience Clinical, LLC, a clinical development and regulatory advisory consultancy, today announced the launch of the Salience Signal-to-Gestalt (S2G) Framework. The methodology addresses a major industry pain point: clinical programs produce massive amounts of digital biomarkers, sensor data, and real-world evidence (RWE) that create an unmanageable flood of false signals using conventional statistical tools, while opaque machine learning algorithms fail to provide regulators the biological plausibility and audit trail they demand.

This problem is addressed by the S2G Framework, which employs a four-tier, Human-in-the-Loop (HITL) pipeline connecting computational screening directly to senior physician judgment:

• Tier 1 – Multi-Source Ingestion & Harmonization: Pulls together high-entropy datasets including clinical trial safety databases, EHRs, continuous sensor streams, and biomarker panels normalizing data syntax and removing background noise.
• Tier 2 – Explainable AI & Signal Detection: Uses auditable algorithms aligned with FDA Good Machine Learning Practice (GMLP), cross-center AI credibility assessment frameworks, and lifecycle management standards (including Predetermined Change Control Plans [PCCP] when applicable for digital endpoints and SaMD) to detect real safety clusters and efficacy trends with end-to-end data provenance. 
• Tier 3 – Mechanistic & Pharmacodynamic Triangulation: Cross-references statistical flags with target pharmacology, receptor binding profiles, and biological pathways to identify true pharmacodynamic effects vs. computational artifacts. 
• Tier 4 – The Salience Gestalt Synthesis: The output filters transition directly to Denis Katz, M.D., Founder and Medical Director of Salience Clinical. Drawing on senior leadership across clinical neuroscience, advanced biologics, Phase III global trials, and BLA/NDA strategy, Dr. Katz synthesizes disparate findings into a unified clinical gestalt—the integrated benefit-risk assessment, target product profile alignment, and scientific justification needed to meet FDA and Advisory Committee scrutiny. 
   

Caption: Figure 1: The Salience S2G Framework — A four-tier pipeline connecting computational data screening to physician-executive clinical gestalt for FDA dossiers.
 

Preserving Clinical Judgment in an Algorithmic Era

“Sponsors are rightfully hesitant to bring AI-derived claims to health authorities because regulators do not accept black boxes, nor do they approve algorithmic correlations without a validated Context of Use,” said Denis Katz, M.D. “The S2G Framework was built around that reality. We deploy explainable computational filters to isolate signals within high-dimensional noise, but the regulatory deliverable is driven entirely by physician-led mechanistic adjudication and clinical gestalt. Sponsors gain the operational speed of advanced analytics without inheriting regulatory audit vulnerability.” 

Strategic Applications

• Agency Briefing Packages: Isolating primary therapeutic signals and biomarker-enriched responder cohorts for Type B, Pre-IND, and Pre-BLA/NDA briefing documents. 
• Safety Signal Adjudication: Distinguishing drug-related adverse events from disease progression and background noise to prevent unmerited clinical holds or excessive post-market warnings. 
• Digital Endpoints and SaMD: Structuring continuous physiological data and software-as-a-medical-device metrics into defensible clinical validation dossiers that meet CDER, CBER, and CDRH standards. 

The S2G Framework is immediately available for active client engagements across biotechnology, pharmaceuticals, and medical devices. Sponsors preparing for upcoming agency interactions can contact Salience Clinical for a confidential regulatory readiness consultation. 

About Salience Clinical, LLC

Salience Clinical, LLC is a focused consulting firm for clinical development, founded by Denis Katz, M.D. Salience helps biopharmaceutical and medical device sponsors with trial design, translational biomarker implementation, safety signal assessment, and critical FDA interactions. Visit salienceclinical.com to learn more.

Media Contact

Organization: Salience Clinical, LLC

Contact Person: Denis Katz, M.D.

Website: https://salienceclinical.com/

Email: Send Email

City: PRINCETON

State: N.J.

Country: United States

Release id: 49085

The post Salience Clinical Introduces S2G Framework Pairing AI Screening with Physician-Executive GestaltSubmissions appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section